- Latest available (Revised)
- Point in Time (09/02/2019)
- Original (As made)
Version Superseded: 22/05/2019
Point in time view as at 09/02/2019. This version of this provision has been superseded.
You are viewing this legislation item as it stood at a particular point in time. A later version of this or provision, including subsequent changes and effects, supersedes this version.
Note the term provision is used to describe a definable element in a piece of legislation that has legislative effect – such as a Part, Chapter or section.
The Human Medicines Regulations 2012, Section 8 is up to date with all changes known to be in force on or before 26 August 2024. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations.
Changes and effects yet to be applied by the editorial team are only applicable when viewing the latest version or prospective version of legislation. They are therefore not accessible when viewing legislation as at a specific point in time. To view the ‘Changes to Legislation’ information for this provision return to the latest version view using the options provided in the ‘What Version’ box above.
8.—(1) In these Regulations (unless the context otherwise requires)—
[F1“the 2001 Directive” means Directive 2001/83/EC of the European Parliament and of the Council on the Community Code relating to medicinal products for human use;]
[F2“active substance” means any substance or mixture of substances intended to be used in the manufacture of a medicinal product and that, when used in its production, becomes an active ingredient of that product intended to exert a pharmacological, immunological or metabolic action with a view to restoring, correcting or modifying physiological functions or to make a medical diagnosis;]
“administer” means administer to a human being—
orally, by injection, or by introduction into the body in any other way; or
by external application (whether or not by direct application to the body),
and any reference in these Regulations to administering anything is to administering it in its existing state or after it has been dissolved or dispersed in, or diluted or mixed with, a substance used as a vehicle;
“advanced therapy medicinal product” means a medicinal product described in Article 2(1)(a) of Regulation (EC) No 1394/2007;
“adverse reaction” means a response to a medicinal product that is noxious and unintended;
“advisory body” has the meaning given by regulation 12(1);
“appropriate practitioner” means an appropriate practitioner within the meaning of regulation 214;
“Article 126a authorisation” means an authorisation granted by the licensing authority under Part 8 of these Regulations;
[F3“assemble”, in relation to a medicinal product or an active substance, includes the various processes of dividing up, packaging and presentation of the product or substance, and “assembly” has a corresponding meaning;]
“biological medicinal product” and “biological substance” have the meaning given in the third indent of paragraph 3.2.1.1.(b) of Annex I to the 2001 Directive;
“blood component” means any of the following—
red cells;
white cells;
platelets; and
plasma;
“the British Pharmacopoeia” means the British Pharmacopoeia referred to in regulation 317;
[F4“brokering” means all activities in relation to the sale or purchase of medicinal products, except for wholesale distribution, that do not include physical handling and that consist of negotiating independently and on behalf of another legal or natural person;]
“business” includes—
a professional practice;
any activity carried on by a body of persons whether corporate or unincorporated; and
the provision of services by or on behalf of the Secretary of State, the Minister for Health, Social Services and Public Safety, the Welsh Ministers or the Scottish Ministers as the case may be under the following enactments—
the National Health Service Act 2006 M1,
the Health and Personal Social Services (Northern Ireland) Order 1972 M2 and the Health and Social Care (Reform) Act (Northern Ireland) 2009 M3,
the National Health Service (Wales) Act 2006 M4,
the National Health Service (Scotland) Act 1978 M5;
[F5“care home”—
in relation to England, has the meaning given by section 3 of the Care Standards Act 2000;
in relation to Wales, has the meaning given by paragraph 1 of Schedule 1 to the Regulation and Inspection of Social Care (Wales) Act 2016;
in relation to Scotland, has the meaning given by paragraph 2 of Schedule 12 to the Public Services Reform (Scotland) Act 2010; and
in relation to Northern Ireland, means a nursing home as defined in article 11 of the Health and Personal Social Services (Quality, Improvement and Regulation) (Northern Ireland) Order 2003;]
“certificate of registration” means a certificate of registration granted by the licensing authority under Part 6 of these Regulations;
“clinical management plan” means a written plan relating to the treatment of an individual patient and agreed by—
the patient;
the doctor or dentist who is a party to the plan; and
any supplementary prescriber who is to prescribe, give directions for administration or administer under the plan;
“clinical trial” has the meaning given by regulation 2 of the Clinical Trials Regulations;
“the Clinical Trials Directive” means Directive 2001/20/EC of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use M6;
“the Clinical Trials Regulations” means the Medicines for Human Use (Clinical Trials) Regulations 2004 M7;
“the Commission” has the meaning given by regulation 9(1);
[F5“Commission Regulation 2016/161” means Commission Delegated Regulation (EU) 2016/161 supplementing Directive 2001/83/EC of the European Parliament and of the Council by laying down detailed rules for the safety features appearing on the packaging of medicinal products for human use;]
“common name” in relation to a medicinal product, active substance or excipient means—
its international non-proprietary name recommended by the World Health Organisation; or
if such a name does not exist, its usual common name;
“community practitioner nurse prescriber” means a person—
who is a registered nurse or a registered midwife; and
against whose name is recorded in the professional register an annotation signifying that the person is qualified to order drugs, medicines and appliances from the Nurse Prescribers' Formulary for Community Practitioners in the current edition of the British National Formulary;
“contravention” includes failure to comply (and “contravene” has a corresponding meaning);
“cosmetic” means any substance or preparation intended to be applied to the surfaces of the human body (including the epidermis, pilary system and hair, nails, lips and external genital organs), or the teeth or buccal mucosa, wholly or mainly for the purpose of—
perfuming them;
cleansing them;
protecting them;
caring for them or keeping them in condition;
modifying their appearance (for aesthetic purposes or otherwise); or
combating body odours or normal body perspiration;
“dentist” means a person registered in the dentists register under section 14 of the Dentists Act 1984 M8;
“Directive 2002/98/EC” means Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC M9;
“Directive 2004/23/EC” means Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells M10;
“disease” includes any injury, ailment or adverse condition, whether of body or mind;
“doctor” means a registered medical practitioner;
“effervescent”, in relation to a tablet or capsule, means containing not less than 75 per cent, by weight of the tablet or capsule, of ingredients included wholly or mainly for the purpose of releasing carbon dioxide when the tablet or capsule is dissolved or dispersed in water;
“electronic communication” means a communication transmitted (whether from one person to another, from one device to another or from a person to a device or vice versa)—
by means of an electronic communications network within the meaning of section 32(1) of the Communications Act 2003 M11; or
by other means but while in an electronic form;
[F6“electronic signature” has the meaning given within Article 3(10) of Regulation (EU) 910/2014 of the European Parliament and of the Council on electronic identification and trust services for electronic transactions in the internal market;]
“the EMA” means the European Medicines Agency established by Regulation (EC) No 726/2004;
“enactment” includes primary and secondary legislation of the devolved administrations in Wales, Scotland and Northern Ireland;
“enforcement authority” means the Secretary of State, the Minister for Health, Social Services and Public Safety or a person on whom a function of enforcing a provision of these Regulations has been conferred by virtue of regulations 323 or 324;
“EU marketing authorisation” means a marketing authorisation granted or renewed by the European Commission under Regulation (EC) No 726/2004;
“European Economic Area” or “EEA” means the European Economic Area created by the EEA agreement;
“the European Pharmacopoeia” means the European Pharmacopoeia published by the European Directorate for the Quality of Medicines;
[F7“excipient” means any constituent of a medicinal product other than the active substance and the packaging material;]
“exempt advanced therapy medicinal product” has the meaning given in regulation 171;
“expert advisory group” has the meaning given by regulation 14(1);
[F8“export” means export, or attempt to export, from the United Kingdom, whether by land, sea or air;]
[F9“external use” in relation to a medicinal product—
means its use by application to the skin, teeth, mucosa of the mouth, throat, nose, ear, eye, vagina or anal canal in circumstances where local action only is necessary and systemic absorption is unlikely to occur; but
does not include its use by means of a throat spray, nasal spray, nasal inhalation or teething preparation or by means of throat pastilles, throat lozenges, throat tablets or nasal drops;]
[F10“falsified medicinal product” means any medicinal product with a false representation of—
its identity, including its packaging and labelling, its name or its composition (other than any unintentional quality defect) as regards any of its ingredients including excipients and the strength of those ingredients;
its source, including its manufacturer, its country of manufacturing, its country of origin or its marketing authorisation holder; or
its history, including the records and documents relating to the distribution channels used;
“Fees Regulations” means [F11the Medicines (Products for Human Use) (Fees) Regulations 2016];]
“the Good Manufacturing Practice Directive” means Commission Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use M12;
“the Health and Care Professions Council register” means the register established and maintained by the Health and Care Professions Council under article 5 of the Health and Social Work Professions Order 2001 M13;
“health care professional” means—
a doctor;
a dentist;
a pharmacist;
a pharmacy technician registered in Part 2 or 5 of the Register of pharmacists and pharmacy technicians established and maintained under article 19(2) of the Pharmacy Order 2010 M14;
a registered nurse;
a registered midwife;
a registered optometrist;
a registered osteopath as defined in section 41 of the Osteopaths Act 1993 M15;
a registered chiropractor as defined in section 43 of the Chiropractors Act 1994 M16;
a person registered as a member of a relevant profession within the meaning of article 2 and paragraph 1 of Schedule 3 to the Health and Social Work Professions Order 2001 M17, other than a social worker, in the Health and Care Professions Council register; or
a person registered in the dental care professionals register established and maintained under section 36B of the Dentists Act 1984 M18 as a member of a profession complementary to dentistry specified by regulation 2 of the General Dental Council (Professions Complementary to Dentistry) Regulations 2006 M19;
“health centre” means a health centre maintained under—
section 2 or 3 of the National Health Service Act 2006 M20;
section 2 or 3 of the National Health Service (Wales) Act 2006 M21;
section 36(1)(b) of the National Health Service (Scotland) Act 1978 M22; or
article 5 of the Health and Personal Social Services (Northern Ireland) Order 1972 M23;
[F5“healthcare institution” has the meaning given by Article 3(2) of Commission Regulation 2016/161;]
“herbal medicinal product” means a medicinal product whose only active ingredients are herbal substances or herbal preparations (or both);
“herbal preparation” means a preparation obtained by subjecting herbal substances to processes such as extraction, distillation, expression, fractionation, purification, concentration or fermentation, and includes a comminuted or powdered herbal substance, a tincture, an extract, an essential oil, an expressed juice or a processed exudate;
“herbal substance” means a plant or part of a plant, algae, fungi or lichen, or an unprocessed exudate of a plant, defined by the plant part used and the botanical name of the plant, either fresh or dried, but otherwise unprocessed;
“homoeopathic medicinal product” means a medicinal product prepared from homoeopathic stocks in accordance with a homoeopathic manufacturing procedure described by—
the European Pharmacopoeia; or
in the absence of such a description in the European Pharmacopoeia, in any pharmacopoeia used officially in an EEA State;
[F5“hospice” means an institution whose primary function is the provision of palliative care to persons resident there who are suffering from a progressive disease in its final stages;]
“hospital” includes a clinic, nursing home or similar institution;
“immediate packaging” in relation to a medicinal product means the container or other form of packaging immediately in contact with the medicinal product;
[F12“import” means import, or attempt to import, into the United Kingdom, whether by land, sea or air;]
“inspector” means a person authorised in writing by an enforcement authority for the purposes of Part 16 (enforcement) (and references to “the enforcement authority”, in relation to an inspector, are to the enforcement authority by whom the inspector is so authorised);
“intermediate product” means a substance which—
has been manufactured for use in the manufacture of medicinal products; and
is intended for further processing by a manufacturer of such products;
“investigational medicinal product” has the meaning given in regulation 2(1) of the Clinical Trials Regulations;
“labelling” in relation to a container or package of medicinal products means affixing to or otherwise displaying on it a notice describing or otherwise relating to the contents (and “label” has a corresponding meaning);
“the licensing authority” has the meaning given by regulation 6(2);
“manufacture”, in relation to a medicinal product, includes any process carried out in the course of making the product, but does not include dissolving or dispersing the product in, or diluting or mixing it with, a substance used as a vehicle for the purpose of administering it;
“manufacturer's licence” has the meaning given by regulation 17(1);
“marketing authorisation” means—
a UK marketing authorisation; or
an EU marketing authorisation;
“medicinal product subject to general sale” has the meaning given in regulation 5(1) (classification of medicinal products);
“the Ministers” is to be construed in accordance with regulation 6(6) to (8);
“name” in relation to a medicinal product means—
where the product has a UK marketing authorisation or traditional herbal registration, the name—
as approved by the licensing authority in granting the authorisation or registration, or
where that name has been varied since that approval, as so amended;
where the product has an EU marketing authorisation, the name—
as approved by the European Commission in granting the authorisation, or
where that name has been varied since that approval, as so amended; and
where the product has an Article 126a authorisation, the name—
as approved by the licensing authority to appear on the packaging and any package leaflet of the product under the authorisation, or
where that name has been varied since that approval, as so amended;
“the Narcotic Drugs Convention” means the Single Convention on Narcotic Drugs signed by the United Kingdom on 30thMarch 1961 as amended by the Protocol Amending the Single Convention on Narcotic Drugs signed by the United Kingdom on 25th March 1972;
“NHS primary dental services” means—
in relation to England, primary dental services under the National Health Service Act 2006;
in relation to Wales, primary dental services under the National Health Service (Wales) Act 2006;
in relation to Scotland, dental services under the National Health Service (Scotland) Act 1978 or personal dental services in connection with a pilot scheme under the National Health Service (Primary Care) Act 1997 M24; and
in relation to Northern Ireland, general dental services under the Health and Personal Social Services (Northern Ireland) Order 1972 or personal dental services in connection with a pilot scheme under the Health Services (Primary Care) (Northern Ireland) Order 1997 M25;
“NHS primary medical services” means—
in relation to England, primary medical services under the National Health Service Act 2006;
in relation to Wales, primary medical services under the National Health Service (Wales) Act 2006;
in relation to Scotland, primary medical services under the National Health Service (Scotland) Act 1978; and
in relation to Northern Ireland, primary medical services under the Health and Personal Social Services (Northern Ireland) Order 1972;
“nurse independent prescriber” means a person who—
is a registered nurse or registered midwife; and
is noted in the professional register as qualified to order drugs, medicines and appliances as a nurse independent prescriber or a nurse independent / supplementary prescriber;
“optometrist independent prescriber” means a person—
who is a registered optometrist; and
against whose name is recorded in the relevant register an annotation signifying that the person is qualified to order drugs, medicines and appliances as an optometrist independent prescriber;
“outer packaging” in relation to a medicinal product means any packaging into which the immediate packaging of the medicinal product is placed;
“package” in relation to a medicinal product, includes—
a container of the product;
any box, packet or other article in which one or more containers of the product are or are to be enclosed; and
any box, packet or other article in which a box, packet or other article mentioned in paragraph (b) or this paragraph is or is to be enclosed;
“package leaflet” in relation to a medicinal product, means a leaflet that accompanies the product and contains information for the user of the product;
“paediatric clinical trial” means a clinical trial conducted in whole or in part on persons under the age of 18 years;
“paediatric investigation plan” means a research and development programme with the purpose of generating data determining the conditions in which a medicinal product may be authorised to treat persons under the age of 18 years;
“the Paediatric Regulation” means Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 M26;
[F13“paramedic independent prescriber” means a person—
who is a registered paramedic; and
against whose name is recorded in the relevant register an annotation signifying that the person is qualified to order drugs, medicines and appliances as a paramedic independent prescriber;]
“periodic safety update report” or “PSUR” has the meaning given in regulation 191 (obligation on holder to submit periodic safety update reports: general requirements);
“pharmacist” means—
in relation to Great Britain a person registered in Part 1 or 4 of the Register of pharmacists and pharmacy technicians maintained under article 19(2) of the Pharmacy Order 2010 M27; and
in relation to Northern Ireland a person registered in the register of pharmaceutical chemists for Northern Ireland or the register of visiting pharmaceutical chemists from a relevant European State maintained under articles 6 and 9 of the Pharmacy (Northern Ireland) Order 1976 M28;
“pharmacist independent prescriber” means a person who—
is a pharmacist; and
is noted in the relevant register as qualified to order drugs, medicines and appliances as a pharmacist independent prescriber;
“the Pharmacovigilance Risk Assessment Committee” means the committee of the EMA established by Article 56(1)(aa) of Regulation (EC) No 726/2004;
“pharmacovigilance system” means a system used by the holder of a marketing authorisation, traditional herbal registration or Article 126a authorisation, or by the licensing authority, to fulfil the tasks and responsibilities set out in Part 11 and designed to monitor the safety of authorised or registered medicinal products and detect any change to their risk-benefit balance;
“pharmacovigilance system master file” means a detailed description of the pharmacovigilance system used by the holder of a marketing authorisation, traditional herbal registration or Article 126a authorisation with respect to one or more authorised or registered medicinal products;
“pharmacy medicine” has the meaning given in regulation 5(5) (classification of medicinal products);
[F14“physiotherapist independent prescriber” means a person—
who is a registered physiotherapist; and
against whose name is recorded in the relevant register an annotation signifying that the person is qualified to order drugs, medicines and appliances as a physiotherapist independent prescriber;
“podiatrist independent prescriber” means a person—
who is a registered podiatrist; and
against whose name is recorded in the relevant register an annotation signifying that the person is qualified to order drugs, medicines and appliances as a podiatrist independent prescriber;]
“post-authorisation efficacy study” means any study relating to a medicinal product to which a marketing authorisation relates that is conducted with the aim of considering the efficacy of that product;
“post-authorisation safety study” means any study relating to a medicinal product to which a marketing authorisation, traditional herbal registration or Article 126a authorisation relates that is conducted with the aim of—
identifying, characterising or quantifying a safety hazard;
confirming the safety profile of the medicinal product; or
measuring the effectiveness of risk management measures;
“prescription only medicine” has the meaning given in regulation 5(3) (classification of medicinal products);
“product information” in relation to a medicinal product means—
the summary of the product characteristics;
the immediate and outer packaging; and
the package leaflet;
“the professional register” means the register maintained by the Nursing and Midwifery Council under article 5 of the Nursing and Midwifery Order 2001 M29;
“the Psychotropic Substances Convention” means the Convention on Psychotropic Substances signed by the United Kingdom on 21st February 1971;
“qualified person”, except in relation to the expression “appropriately qualified person”, means—
a person who satisfies the requirements specified in Part 1 or 2 of Schedule 7; or
where an application for a licence is made before 30th April 2013, in so far as the application relates to activities in respect of traditional herbal medicinal products, a person who has been engaged in activities in respect of traditional herbal medicinal products equivalent to those in Part 3 of Schedule 7 on or before 30th April 2011 and continues to be so engaged at the time when the application is made;
[F15“radiation emergency” has the meaning given by regulation 2(1) of the Radiation (Emergency Preparedness and Public Information) Regulations 2001;]
“radionuclide” means a radioactive isotope;
“radionuclide generator” means any system incorporating a fixed parent radionuclide from which is produced a daughter radionuclide which is to be removed by elution or by any other method and is to be used in a radiopharmaceutical;
“radionuclide kit” means any preparation to be reconstituted or combined with radionuclides in the final radiopharmaceutical, usually prior to its administration;
“radionuclide precursor” means any radionuclide produced for the radio-labelling of another substance prior to administration, other than a radionuclide that is incorporated in or produced from a generator or is included in a radiopharmaceutical;
“radiopharmaceutical” means a medicinal product which, when ready for use, contains one or more radionuclides included for a medicinal purpose;
[F16“registered dietitian” means a person registered in Part 4 of the Health and Care Professions Council register;]
“registered midwife” means a person registered in the Midwives Part of the professional register;
“registered nurse” means a person registered in the Nurses Part or the Specialist Community Public Health Nurses Part of the professional register;
“registered optometrist” means a person whose name is entered in the register of optometrists maintained under section 7(a) of the Opticians Act 1989 M30 or the register of visiting optometrists from relevant European States maintained under section 8B(1)(a) M31 of that Act;
[F17“registered paramedic” means a person who is registered in Part 8 of the Health and Care Professions Council register;]
“registered pharmacy” means—
in relation to Great Britain, premises entered in the register required to be kept under article 19 of the Pharmacy Order 2010 for the purposes of sections 74A and 74J of the Medicines Act 1968 M32; and
in relation to Northern Ireland, premises entered in the register required to be kept under section 75 M33 of the Medicines Act 1968;
[F18“registered physiotherapist” means a person registered in Part 9 of the Health and Care Professions Council register;
“registered podiatrist” means a person registered in Part 2 of the Health and Care Professions Council register;
“registered radiographer” means a person registered in Part 11 of the Health and Care Professions Council register;]
“registrable homoeopathic medicinal product” means a homoeopathic medicinal product to which regulation 102 applies;
[F19“Regulation (EC) No 726/2004” means Regulation (EC) 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency;]
“Regulation (EC) No 1394/2007” means Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 M34;
“Regulation (EC) No 1234/2008” means Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products M35;
“the relevant EU provisions” means the provisions of legislation of the European Union relating to medicinal products for human use, except to the extent that any other enactment provides for any function in relation to any such provision to be exercised otherwise than by the licensing authority;
“relevant European State” means an EEA State or Switzerland;
“relevant medicinal product” has the meaning given by regulation 48;
“the relevant register” means—
in relation to a pharmacist—
in Great Britain, Part 1 of the Register of pharmacists and pharmacy technicians maintained under article 19(2) of the Pharmacy Order 2010, or
in Northern Ireland, the register maintained in pursuance of articles 6 and 9 of the Pharmacy (Northern Ireland) Order 1976;
in relation to a registered nurse or registered midwife, the professional register;
in relation to a registered optometrist, the register of optometrists maintained under section 7(a) of the Opticians Act 1989 or the register of visiting optometrists from relevant European States maintained under section 8B(1)(a) of that Act; and
“retail pharmacy business” means a business (other than a professional practice carried on by a doctor or dentist) which consists of or includes the retail sale of medicinal products that are not subject to general sale;
“risk management plan” means a detailed description of the risk management system;
“risk management system” means a set of pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to a medicinal product, including an assessment of the effectiveness of those activities and interventions;
“serious adverse reaction” means an adverse reaction that—
results in a person's death;
threatens a person's life;
results in a person being hospitalised as an inpatient or prolongs a person's existing stay in hospital;
results in a person's persistent or significant disability or incapacity; or
results in a congenital anomaly or birth defect;
“special medicinal product” means a product within the meaning of regulation 167 or any equivalent legislation in an EEA State other than the United Kingdom;
“substance” means any matter regardless of its origins and includes—
human substances (such as human blood and human blood products);
animal substances (such as micro-organisms, whole animals, parts of organs, animal secretions, toxins, extracts and blood products);
vegetable substances (such as micro-organisms, plants, parts of plants, vegetable secretions and extracts);
chemical substances (such as elements, naturally occurring chemical materials and chemical products obtained by chemical change or synthesis); and
gases and vapours;
“the summary of the product characteristics” in relation to a medicinal product means—
where the product has a UK marketing authorisation or traditional herbal registration, the summary of the product characteristics—
as approved by the licensing authority in granting the authorisation or registration, or
where the summary has been varied since that approval, as so amended; or
where the product has an EU marketing authorisation, the summary of the product characteristics—
as approved by the European Commission in granting the authorisation, or
where the summary has been varied since that approval, as so amended;
“supplementary prescriber” means a person who is noted in the relevant register as qualified to order drugs, medicines and appliances as a supplementary prescriber (or, in the case of a registered nurse or registered midwife, as a nurse independent/supplementary prescriber) and is—
“suspected” in relation to an adverse reaction means that there is at least a reasonable possibility of there being a causal relationship between a medicinal product and an adverse event;
[F29“therapeutic radiographer independent prescriber” means a person—
who is a registered radiographer; and
against whose name is recorded in the relevant register—
an entitlement to use the title “therapeutic radiographer”; and
an annotation signifying that the person is qualified to order drugs, medicines and appliances as a therapeutic radiographer independent prescriber;]
“third country” means a country or territory outside the EEA:
“traditional herbal medicinal product” means a herbal medicinal product to which regulation 125 applies;
“traditional herbal registration” means a traditional herbal registration granted by the licensing authority under these Regulations;
“UK marketing authorisation” means a marketing authorisation granted by the licensing authority under—
Part 5 of these Regulations; or
Chapter 4 of Title III to the 2001 Directive (mutual recognition and decentralised procedure);
“vaccine” means an antigenic substance which consists wholly or partly of—
any micro-organisms, viruses or other organisms in any state;
any toxins of microbial origin which have been detoxified (toxoids); or
any extracts or derivatives of any micro-organisms or of any viruses,
being substances which, when administered to human beings, are used for the prevention of specific diseases;
“wholesale dealer's licence” has the meaning given by regulation 18(1).
(2) In these Regulations, references to distribution of a product by way of wholesale dealing are to be construed in accordance with regulation [F3018(4) and (5)].
(3) In these Regulations, references to selling by retail, or to retail sale, are references to selling a product to a person who buys it otherwise than for a purpose specified in regulation [F3118(5)].
(4) In these Regulations, references to supplying anything in circumstances corresponding to retail sale are references to supplying it, otherwise than by way of sale, to a person who receives it otherwise than for a purpose specified in regulation [F3218(5)];
(5) References in these Regulations to the terms of—
(a)a marketing authorisation include the information supplied in relation to the authorisation in accordance with—
(i)regulation 50 and Schedule 8, and
(ii)(if appropriate) Schedule 10 (national homoeopathic products),
as updated in accordance with regulation 57, as approved upon grant under regulation 49 and as varied under regulation 68;
(b)a certificate of registration include the information supplied in relation to the certificate in accordance with regulation 103, as approved upon grant under regulation 103 and as varied under regulation 110; and
(c)a traditional herbal registration include the information supplied in relation to the registration in accordance with regulation 128 and Schedule 12, as updated in accordance with regulation 129, as approved upon grant under regulation 127 and as varied under regulation 135.
(6) References in these Regulations to a condition of—
(a)a marketing authorisation is to a condition to which the authorisation is subject by virtue of regulation 59(1) or 60(1); and
(b)a certificate of registration is to a condition to which the certificate is subject by virtue of regulation 105(1).
(7) For the purposes of these Regulations medicinal products are of the same description if—
(a)they are manufactured to the same specification, and
(b)they are in the same pharmaceutical form.
[F33(8) References in these Regulations to—
(a)good manufacturing practice for active substances relate to the principles and guidelines for good manufacturing practice adopted by the European Commission under the third paragraph of Article 47 of the 2001 Directive;
(b)good distribution practice for active substances relate to the guidelines on good distribution practices for active substances adopted by the European Commission under the fourth paragraph of Article 47 of the 2001 Directive.]
Textual Amendments
F1Words in reg. 8(1) substituted (11.11.2013) by The Human Medicines (Amendment) (No. 2) Regulations 2013 (S.I. 2013/2593), regs. 1(2), 2(2)
F2Words in reg. 8(1) inserted (20.8.2013) by The Human Medicines (Amendment) Regulations 2013 (S.I. 2013/1855), regs. 1(1), 3(a)(i)
F3Words in reg. 8(1) substituted (20.8.2013) by The Human Medicines (Amendment) Regulations 2013 (S.I. 2013/1855), regs. 1(1), 3(a)(ii)
F4Words in reg. 8(1) inserted (20.8.2013) by The Human Medicines (Amendment) Regulations 2013 (S.I. 2013/1855), regs. 1(1), 3(a)(iii)
F5Words in reg. 8(1) inserted (9.2.2019) by The Human Medicines (Amendment) Regulations 2019 (S.I. 2019/62), regs. 1, 3 and words in reg. 8(1) inserted (N.I.) (9.2.2019) by The Human Medicines (Amendment) Regulations 2019 (S.R. 2019/10), regs. 1, 3
F6Words in reg. 8(1) inserted (22.7.2016) by The Electronic Identification and Trust Services for Electronic Transactions Regulations 2016 (S.I. 2016/696), reg. 1, Sch. 3 para. 8(1)
F7Words in reg. 8(1) inserted (20.8.2013) by The Human Medicines (Amendment) Regulations 2013 (S.I. 2013/1855), regs. 1(1), 3(a)(iv)
F8Words in reg. 8(1) substituted (20.8.2013) by The Human Medicines (Amendment) Regulations 2013 (S.I. 2013/1855), regs. 1(1), 3(a)(v)
F9Words in reg. 8(1) inserted (1.10.2017) by The Human Medicines (Amendment) Regulations 2017 (S.I. 2017/715), regs. 1, 3(2)(a) and words in reg. 8(1) inserted (N.I.) (1.10.2017) by The Human Medicines (Amendment) Regulations 2017 (S.R. 2017/241), regs. 1, 3(2)(a)
F10Words in reg. 8(1) inserted (20.8.2013) by The Human Medicines (Amendment) Regulations 2013 (S.I. 2013/1855), regs. 1(1), 3(a)(vi)
F11Words in reg. 8(1) substituted (1.4.2016) by The Medicines (Products for Human Use) (Fees) Regulations 2016 (S.I. 2016/190), regs. 1, 62
F12Words in reg. 8(1) inserted (20.8.2013) by The Human Medicines (Amendment) Regulations 2013 (S.I. 2013/1855), regs. 1(1), 3(a)(vii)
F13Words in reg. 8(1) inserted (1.4.2018) by The Human Medicines (Amendment) Regulations 2018 (S.I. 2018/199), regs. 1, 3(2)(a) and words in reg. 8(1) inserted (N.I.) (1.4.2018) by The Human Medicines (Amendment) Regulations 2018 (S.R. 2018/64), regs. 1, 3(2)(a)
F14Words in reg. 8(1) inserted (20.8.2013) by The Human Medicines (Amendment) Regulations 2013 (S.I. 2013/1855), regs. 1(1), 3(a)(viii)
F15Words in reg. 8(1) inserted (1.4.2018) by The Human Medicines (Amendment) Regulations 2018 (S.I. 2018/199), regs. 1, 3(2)(b) and words in reg. 8(1) inserted (N.I.) (1.4.2018) by The Human Medicines (Amendment) Regulations 2018 (S.R. 2018/64), regs. 1, 3(2)(b)
F16Words in reg. 8(1) inserted (E.W.S.) (1.4.2016) by The Human Medicines (Amendment) Regulations 2016 (S.I. 2016/186), regs. 1, 3(2)(b) and words in reg. 8(1) inserted (N.I.) (1.4.2016) by The Human Medicines (Amendment) Regulations 2016 (S.R. 2016/407), regs. 1, 3(2)(b)
F17Words in reg. 8(1) inserted (1.4.2018) by The Human Medicines (Amendment) Regulations 2018 (S.I. 2018/199), regs. 1, 3(2)(c) and words in reg. 8(1) inserted (N.I.) (1.4.2018) by The Human Medicines (Amendment) Regulations 2018 (S.R. 2018/64), regs. 1, 3(2)(c)
F18Words in reg. 8(1) inserted (E.W.S.) (1.4.2016) by The Human Medicines (Amendment) Regulations 2016 (S.I. 2016/186), regs. 1, 3(2)(c) and words in reg. 8(1) inserted (N.I.) (1.4.2016) by The Human Medicines (Amendment) Regulations 2016 (S.R. 2016/407), regs. 1, 3(2)(c)
F19Words in reg. 8(1) substituted (11.11.2013) by The Human Medicines (Amendment) (No. 2) Regulations 2013 (S.I. 2013/2593), regs. 1(2), 2(3)
F20Words in reg. 8(1) inserted (1.10.2017) by The Human Medicines (Amendment) Regulations 2017 (S.I. 2017/715), regs. 1, 3(2)(b)(i) and words in reg. 8(1) inserted (N.I.) (1.10.2017) by The Human Medicines (Amendment) Regulations 2017 (S.R. 2017/241), regs. 1, 3(2)(b)(i)
F21Words in reg. 8(1) inserted (1.4.2018) by The Human Medicines (Amendment) Regulations 2018 (S.I. 2018/199), regs. 1, 3(2)(d)(i) and words in reg. 8(1) inserted (N.I.) (1.4.2018) by The Human Medicines (Amendment) Regulations 2018 (S.R. 2018/64), regs. 1, 3(2)(d)(i)
F22Word in reg. 8(1) omitted (1.10.2017) by virtue of The Human Medicines (Amendment) Regulations 2017 (S.I. 2017/715), regs. 1, 3(2)(b)(ii) and word in reg. 8(1) omitted (N.I.) (1.10.2017) by virtue of The Human Medicines (Amendment) Regulations 2017 (S.R. 2017/241), regs. 1, 3(2)(b)(ii)
F23Words in reg. 8(1) inserted (1.10.2017) by The Human Medicines (Amendment) Regulations 2017 (S.I. 2017/715), regs. 1, 3(2)(b)(iii) and words in reg. 8(1) inserted (N.I.) (1.10.2017) by The Human Medicines (Amendment) Regulations 2017 (S.R. 2017/241), regs. 1, 3(2)(b)(iii)
F24Word in reg. 8(1) omitted (1.4.2018) by virtue of The Human Medicines (Amendment) Regulations 2018 (S.I. 2018/199), regs. 1, 3(2)(d)(ii) and word in reg. 8(1) omitted (N.I.) (1.4.2018) by virtue of The Human Medicines (Amendment) Regulations 2018 (S.R. 2018/64), regs. 1, 3(2)(d)(ii)
F25Words in reg. 8(1) inserted (1.4.2018) by The Human Medicines (Amendment) Regulations 2018 (S.I. 2018/199), regs. 1, 3(2)(d)(iii) and words in reg. 8(1) inserted (N.I.) (1.4.2018) by The Human Medicines (Amendment) Regulations 2018 (S.R. 2018/64), regs. 1, 3(2)(d)(iii)
F26Word in reg. 8(1) inserted (1.4.2018) by The Human Medicines (Amendment) Regulations 2018 (S.I. 2018/199), regs. 1, 3(2)(e) and word in reg. 8(1) inserted (N.I.) (1.4.2018) by The Human Medicines (Amendment) Regulations 2018 (S.R. 2018/64), regs. 1, 3(2)(e)
F27Word in reg. 8(1) omitted (E.W.S.) (1.4.2016) by virtue of The Human Medicines (Amendment) Regulations 2016 (S.I. 2016/186), regs. 1, 3(2)(d)(i) and word in reg. 8(1) omitted (N.I.) (1.4.2016) by virtue of The Human Medicines (Amendment) Regulations 2016 (S.R. 2016/407), regs. 1, 3(2)(d)(i)
F28Words in reg. 8(1) inserted (E.W.S.) (1.4.2016) by The Human Medicines (Amendment) Regulations 2016 (S.I. 2016/186), regs. 1, 3(2)(d)(ii) and words in reg. 8(1) inserted (N.I.) (1.4.2016) by The Human Medicines (Amendment) Regulations 2016 (S.R. 2016/407), regs. 1, 3(2)(d)(ii)
F29Words in reg. 8(1) inserted (E.W.S.) (1.4.2016) by The Human Medicines (Amendment) Regulations 2016 (S.I. 2016/186), regs. 1, 3(2)(a) and words in reg. 8(1) inserted (N.I.) (1.4.2016) by The Human Medicines (Amendment) Regulations 2016 (S.R. 2016/407), regs. 1, 3(2)(a)
F30Words in reg. 8(2) substituted (E.W.S.) (1.10.2015) by The Human Medicines (Amendment) (No. 3) Regulations 2015 (S.I. 2015/1503), regs. 1, 3(2) and words in reg. 8(2) substituted (N.I.) (1.10.2015) by The Human Medicines (Amendment) (No.3) Regulations 2015 (S.R. 2015/354), regs. 1, 3(2)
F31Word in reg. 8(3) substituted (E.W.S.) (1.10.2015) by The Human Medicines (Amendment) (No. 3) Regulations 2015 (S.I. 2015/1503), regs. 1, 3(3) and word in reg. 8(3) substituted (N.I.) (1.10.2015) by The Human Medicines (Amendment) (No.3) Regulations 2015 (S.R. 2015/354), regs. 1, 3(3)
F32Word in reg. 8(4) substituted (E.W.S.) (1.10.2015) by The Human Medicines (Amendment) (No. 3) Regulations 2015 (S.I. 2015/1503), regs. 1, 3(4) and word in reg. 8(4) substituted (N.I.) (1.10.2015) by The Human Medicines (Amendment) (No.3) Regulations 2015 (S.R. 2015/354), regs. 1, 3(4)
F33Reg. 8(8) inserted (20.8.2013) by The Human Medicines (Amendment) Regulations 2013 (S.I. 2013/1855), regs. 1(1), 3(b)
Modifications etc. (not altering text)
C1Reg. 8(1) applied (with modifications) by The Medicines for Human Use (Clinical Trials) Regulations 2004 (S.I. 2004/1031), reg 47(1), Sch. 9 (as substituted (14.8.2012) by S.I. 2012/1916, reg. 1(2), Sch. 34 paras. 57(b), 64 (with Sch. 32))
Marginal Citations
M6OJ No L 121, 1.5.2001, p.34. Directive 2001/20/EC was last amended by Regulation (EC) No 596/2009 (OJ No L 188, 18.7.2009, p.14).
M7S.I. 2004/1031, to which there are amendments not relevant to these Regulations.
M81984 c.24. Section 14 was substituted by the Dentists Act 1984 (Amendment) Order 2005 (S.I. 2005/2011) articles 2 and 6 and further amended by the European Qualifications (Health and Social Care Professions) Regulations 2007 (S.I. 2007/3101), regulations 109 and 111. Other amendments of the Dentists Act are not relevant to these Regulations.
M9OJ No L 33, 8.2.2003, p. 30.
M10OJ No L 102, 7.4.2004, p. 48.
M12OJ L 91, 30.3.2004, p.25.
M13S.I. 2002/254, as amended by S.I. 2009/1182. There are other amendments that are not relevant.
M151993 c.21. Section 41 was amended by S.I. 2007/3101 regulations 206 and 214.
M17S.I. 2002/254. Relevant amendments were made by S.I. 2004/2033, S.I. 2009/1182, S.I. 2010/233 and the Health and the Social Care Act 2012 (2012 c.7).
M181984 c.24. Section 36B was inserted by S.I. 2005/2011, articles 2(1) and 29.
M19S.I. 2006/1440, Schedule.
M221978 c.29. Concurrent functions under section 36(1) were transferred to the National Waiting Times Board by article 4(2)(c) and (4) of S.S.I. 2002/305.
M23S.I. 1972/1265 (N.I. 14), as amended by S.I. 1984/1158 (N.I. 8), S.I. 1986/595 ( N.I. 4) and 2004/311 (N.I. 2).
M26OJ No L 378, 27.12.2006, p.1. Regulation (EC) No 1901/2006, as amended by Regulation (EC) No 1902/2006 (OJ No L 378, 27.12.2006, p.20) .
M28S.I. 1976/1213 (N.I. 22), as amended by S.R. 2008 No. 192.
M29S.I. 2002/253, as amended by S.I. 2009/1182.
M301989 c.44; section 7(a) was amended by S.I. 2005/848, articles 2 and 7(1).
M31Section 8B was inserted by S.I. 2007/3101, regulations 178 and 180.
M321968 c.67. Sections 74A and 74J were inserted by article 68 of and paragraph 1 of Schedule 4 to S.I. 2010/231.
M33Section 75 was amended by article 68 of and paragraph 1 of Schedule 4 to S.I. 2010/231
M34OJ No L 324, 10.12.2007, p.121.
M35OJ No L 334, 12.12.2008, p.7.
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
The Whole Instrument without Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument without Schedules you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument without Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: